Organon OGN Other Non-Opiod Pain, Bone and Dermatology — Revenue

Other product segments

Similar metrics at other companies

ZTSDermatology — Revenue

$398M-15.9%

ACRSDermatology Therapeutics — Revenue

$1.27M-4.6%

FLYWPlatform And Other Revenues — Revenue

$31.85M+1.7%

EQIXNon-recurring revenues — Revenue

$248M+119%

ZTSPain and sedation — Revenue

$217M-2.7%

LENOther revenues — Revenue

$331.4M-6.8%

FAQ

What is Organon's other non-opiod pain, bone and dermatology — revenue?

Organon (OGN) reported other non-opiod pain, bone and dermatology — revenue of $68M in Q1 2026.

How has Organon's other non-opiod pain, bone and dermatology — revenue changed year-over-year?

Organon's other non-opiod pain, bone and dermatology — revenue decreased by 0.0% year-over-year, from $68M to $68M.

What is the long-term trend for Organon's other non-opiod pain, bone and dermatology — revenue?

Over 4 years (2021 to 2025), Organon's other non-opiod pain, bone and dermatology — revenue has grown at a 1.0% compound annual growth rate (CAGR), from $288M to $300M.

What does other non-opiod pain, bone and dermatology — revenue mean?

This metric represents the total net sales generated from the company's portfolio of non-opioid pain management, bone health, and dermatological pharmaceutical products. It reflects the market demand and commercial performance of these specific therapeutic categories within the broader established medicines division. Monitoring this revenue stream helps investors assess the stability and growth trajectory of the company's legacy product lines outside of its core women's health and biosimilar focus areas.